http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Feb 2026 21:31:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Rajavelu+Esther/25969788.html si-local-file:///var/storage/secattach/20260209/25969788.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Rajavelu+Esther/25969788.html Mon, 09 Feb 2026 21:31:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Rajavelu+Esther/25969788.html si-local-file:///var/storage/secattach/20260209/25969788.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Rajavelu+Esther/25969788.html Mon, 09 Feb 2026 21:31:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Keutzer+Timothy/25969765.html si-local-file:///var/storage/secattach/20260209/25969765.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Keutzer+Timothy/25969765.html Mon, 09 Feb 2026 21:10:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Keutzer+Timothy/25969765.html si-local-file:///var/storage/secattach/20260209/25969765.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+06++Filed+by%3A+Keutzer+Timothy/25969765.html Mon, 09 Feb 2026 21:10:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Keutzer+Timothy/25950032.html si-local-file:///var/storage/secattach/20260205/25950032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Keutzer+Timothy/25950032.html Thu, 05 Feb 2026 06:30:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Keutzer+Timothy/25950032.html si-local-file:///var/storage/secattach/20260205/25950032.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Keutzer+Timothy/25950032.html Thu, 05 Feb 2026 06:30:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Rajavelu+Esther/25948906.html si-local-file:///var/storage/secattach/20260204/25948906.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Rajavelu+Esther/25948906.html Wed, 04 Feb 2026 21:44:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Rajavelu+Esther/25948906.html si-local-file:///var/storage/secattach/20260204/25948906.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Spero+Therapeutics%2C+Inc.++For%3A+Feb+02++Filed+by%3A+Rajavelu+Esther/25948906.html Wed, 04 Feb 2026 21:44:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jan+30/25924369.html si-local-file:///var/storage/secattach/20260130/25924369.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jan+30/25924369.html Fri, 30 Jan 2026 17:01:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jan+30/25924369.html si-local-file:///var/storage/secattach/20260130/25924369.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Jan+30/25924369.html Fri, 30 Jan 2026 17:01:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Dec+19/25762373.html si-local-file:///var/storage/secattach/20251219/25762373.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Dec+19/25762373.html Fri, 19 Dec 2025 08:26:00 -0500 O.30518154 SPRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Dec+19/25762373.html si-local-file:///var/storage/secattach/20251219/25762373.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Spero+Therapeutics%2C+Inc.++For%3A+Dec+19/25762373.html Fri, 19 Dec 2025 08:26:00 -0500 O.30518154 SPRO http://www.streetinsider.com/Corporate+News/GSK+resubmits+drug+application+for+Spero%27s+antibiotic+treatment/25762287.html <p>Spero Therapeutics Inc. (NASDAQ: SPRO) announced that development partner GSK filed a New Drug Application resubmission to the FDA for tebipenem HBr, an oral carbapenem antibiotic for treating complicated urinary tract infections, including pyelonephritis.</p><p>The resubmission triggers a $25 million milestone payment to Spero, expected in the first quarter of 2026, according to the company's statement.</p><p>The application is supported by results from the Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025 following a planned interim analysis. Trial results were presented at the IDWeek conference in October 2025.</p><p>Spero has granted GSK exclusive licensing rights to commercialize tebipenem http://www.streetinsider.com/Corporate+News/GSK+resubmits+drug+application+for+Spero%27s+antibiotic+treatment/25762287.html Fri, 19 Dec 2025 08:01:39 -0500 SPRO http://www.streetinsider.com/FDA/GSK+resubmits+drug+application+for+Spero%27s+antibiotic+treatment/25762287.html <p>Spero Therapeutics Inc. (NASDAQ: SPRO) announced that development partner GSK filed a New Drug Application resubmission to the FDA for tebipenem HBr, an oral carbapenem antibiotic for treating complicated urinary tract infections, including pyelonephritis.</p><p>The resubmission triggers a $25 million milestone payment to Spero, expected in the first quarter of 2026, according to the company's statement.</p><p>The application is supported by results from the Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025 following a planned interim analysis. Trial results were presented at the IDWeek conference in October 2025.</p><p>Spero has granted GSK exclusive licensing rights to commercialize tebipenem http://www.streetinsider.com/FDA/GSK+resubmits+drug+application+for+Spero%27s+antibiotic+treatment/25762287.html Fri, 19 Dec 2025 08:01:39 -0500 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Press+Releases/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html <p>CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FfytJI_Ad87-lr8QvTd773C2kdbCLXqABVVzCviWa05XdXi0KRmk9Px16EmxhKFI0MUh_jImLW4X3RInUj94kCBC1F5XcXnLk7-WuwnhkHs=" rel="nofollow" target="_blank">Spero Therapeutics</a>, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026.</p> http://www.streetinsider.com/Globe+Newswire/Spero+Announces+NDA+Resubmission+of+Tebipenem+HBr+by+GSK+to+the+FDA+for+the+Treatment+of+Complicated+Urinary+Tract+Infections%2C+Including+Pyelonephritis/25762252.html Fri, 19 Dec 2025 08:00:00 -0500 A.06822034 A.60012002 O.20026344 O.30518154 O.69857460 SPRO